Tirzepatide vs AOD-9604

Side-by-side comparison of Tirzepatide, AOD-9604 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Tirzepatide Tirzepatide (GIP/GLP-1 Dual Agonist) Weight Loss AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss
Basics
Molecular type Dual GIP/GLP-1 Receptor AgonisthGH C-terminal Fragment
Amino acids 3916
Molecular weight 4,813.5 Da1,815.1 Da
Half-life ~5 days~30 min
Route(s) Subcutaneous injectionSubcutaneous, Oral (research)
Mechanism & Research
Primary mechanism Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two inc… AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri…
Research status FDA Approved Research Compound
Evidence summary Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark… AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si…
Protocol & Dosing
Typical dose 2.5mg → 15mg weekly300–500 mcg/day
Frequency Once weeklyOnce daily
Duration Ongoing (chronic)8–12 weeks
Timing Same day each week, any time of dayPre-workout or morning on empty stomach (for metabolic effects)
Safety
Common side effects
  • Nausea (33–40%)
  • Diarrhoea (17–22%)
  • Vomiting (11–13%)
  • Constipation (11–12%)
  • Injection site redness
  • Mild flushing
  • Headache (transient)
Contraindications
  • Personal/family history of MEN2 or medullary thyroid carcinoma
  • Known GIP or GLP-1 receptor agonist hypersensitivity
  • Severe renal impairment (caution)
  • Active cancer (theoretical, given GH receptor homology)
  • Pregnancy (no data)
Anti-doping Not Prohibited Prohibited (WADA S2)
Deeper reading
Related peptides Semaglutide, AOD-9604, Tesamorelin Semaglutide, Ipamorelin, Tesamorelin
Full profile Read full Tirzepatide profile → Read full AOD-9604 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.